Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued Sort descending
Inlyta (RFA) Axitinib Metastatic Renal Cell Carcinoma N/A Complete
TBC avapritinib Advanced Systemic Mastocytosis Pending
TBC ferric carboxymaltose Iron deficiency anemia Pending
NA icatibant Hereditary Angioedema Active
TBC rozanolixizumab Generalized myasthenia gravis (gMG). Pending
TBC talquetamab Relapsed or refractory multiple myeloma Pending
Treanda (in combination with rituximab) Bendamustine hydrochloride Chronic Lymphocytic Leukemia Withdrawn
Imbruvica Ibrutinib
Viibryd vilazodone CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Imbruvica ibrutinib CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer